➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
McKesson
Mallinckrodt

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDREA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Hydrea

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00127972 ↗ 2NN & CHARM Long-Term Follow-up Study Completed Boehringer Ingelheim Phase 4 2004-02-01 It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
NCT00127972 ↗ 2NN & CHARM Long-Term Follow-up Study Completed International Antiviral Therapy Evaluation Center Phase 4 2004-02-01 It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
NCT01098084 ↗ Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed Janssen-Cilag Ltd. Phase 2 2008-11-01 The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.
NCT01098084 ↗ Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed Groupe Francophone des Myelodysplasies Phase 2 2008-11-01 The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrea

Condition Name

Condition Name for Hydrea
Intervention Trials
Sickle Cell Disease 3
Sickle Cell Anemia 2
Stroke 2
HIV Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrea
Intervention Trials
Anemia, Sickle Cell 4
Stroke 2
Neoplasms 2
Thrombocytosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrea

Trials by Country

Trials by Country for Hydrea
Location Trials
United States 7
Nigeria 2
France 2
Denmark 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrea
Location Trials
Tennessee 2
Minnesota 1
Texas 1
Georgia 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrea

Clinical Trial Phase

Clinical Trial Phase for Hydrea
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrea
Clinical Trial Phase Trials
Not yet recruiting 3
Completed 2
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrea

Sponsor Name

Sponsor Name for Hydrea
Sponsor Trials
Aminu Kano Teaching Hospital 3
National Cancer Institute (NCI) 2
Vanderbilt University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrea
Sponsor Trials
Other 17
NIH 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Moodys
McKesson
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.